Related Experiment Video

Updated: May 24, 2026

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

Neurobehavioral dysfunction in patients with subcortical vascular mild cognitive impairment and subcortical vascular

Juhee Chin1, Sang Won Seo, Sook Hui Kim

  • 1Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

The Clinical Neuropsychologist
|February 22, 2012
PubMed

Insights

Subcortical vascular mild cognitive impairment (svMCI) shows neuropsychiatric symptoms, potentially indicating a prodromal stage of subcortical vascular dementia (SVaD). Early detection of these symptoms is crucial for managing vascular cognitive impairment.

Area of Science:

  • Neurology
  • Neuropsychology
  • Geriatrics

Background:

  • Amnestic mild cognitive impairment (MCI) is a precursor to Alzheimer's disease.
  • Subcortical vascular MCI (svMCI) is recognized as a potential prodromal stage of subcortical vascular dementia (SVaD).

Purpose of the Study:

  • To investigate and compare neuropsychiatric features in patients with svMCI, SVaD, and healthy controls.
  • To explore the progression of neuropsychiatric symptoms in vascular cognitive impairment.

Main Methods:

  • Neuropsychiatric assessments were conducted on 31 svMCI patients, 42 SVaD patients, and 28 healthy controls.
  • The Neuropsychiatric Inventory (NPI) and Frontal Behavioral Inventory (FBI) were utilized for symptom evaluation.

Main Results:

  • SVaD patients exhibited the most severe neuropsychiatric symptoms, followed by svMCI patients, and then healthy controls.
  • Negative symptoms were more predominant than positive symptoms in both svMCI and SVaD patients, with a stronger tendency in SVaD.
  • svMCI patients displayed a milder but similar pattern of neuropsychiatric symptoms compared to SVaD patients.

Conclusions:

  • Neuropsychiatric abnormalities in svMCI suggest it may be a prodromal stage of SVaD.
  • Vascular cognitive impairment begins with both negative and positive neuropsychiatric symptoms, progressing to more severe negative symptoms.
  • Behavioral ratings can aid in the early detection of vascular cognitive impairment associated with small vessel disease.

More Related Videos

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...